Welcome to our dedicated page for Elite Pharmaceuticals SEC filings (Ticker: ELTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Following Elite Pharmaceuticals Inc.’s pipeline of controlled-release opioids and niche generics means combing through pages of DEA inventories, FDA ANDA milestones, and complex revenue-sharing agreements. If you’ve ever typed “What does Elite Pharmaceuticals report in their SEC filings?” or looked for “Elite Pharmaceuticals insider trading Form 4 transactions,” you know the challenge: disclosures scatter across multiple forms and arrive on EDGAR without warning.
Our filings hub solves that problem. Real-time alerts surface every Elite Pharmaceuticals Form 4 insider transactions filing the instant it posts, while AI-powered summaries translate the legal language inside each 8-K material event. Need the latest Elite Pharmaceuticals quarterly earnings report 10-Q filing? We pair it with an actionable earnings report filing analysis so you can spot shifts in controlled-release gross margins in seconds. Annual report 10-K simplified write-ups break down DEA compliance risk, ANDA status, and partner royalty streams—information investors track before decisive moves. The dashboard archives every form—10-K, 10-Q, 8-K, S-3, DEF 14A—so nothing slips through.
Beyond headline numbers, our platform answers natural questions like “understanding Elite Pharmaceuticals SEC documents with AI” or “Elite Pharmaceuticals proxy statement executive compensation.” You’ll see insider buying patterns, executive stock transactions Form 4 comparisons, and segment revenue charts—without scrolling through 300 pages. In short, it’s Elite Pharmaceuticals SEC filings explained simply: comprehensive coverage, AI-powered summaries, and expert context that turns regulatory data into clear, timely insight.
Elite Pharmaceuticals (ELTP) filed an 8-K noting it filed its Form 10‑Q for the quarter ended September 30, 2025 and issued a press release with those results. The company will host a conference call on November 17, 2025 at 11:30 AM EST to provide a business update and answer pre-submitted stockholder questions.
Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference number 98840. Financial questions may be emailed to dianne@elitepharma.com by 7:00 PM EST on November 14, 2025. An audio replay will be available at https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (ELTP) reported a strong Q2 FY2026. Total revenue reached $36,321,704 for the quarter, up from $18,880,345 a year ago, driven by manufacturing fees. Gross profit was $14,073,033. Income from operations rose to $8,213,746. A $7,519,649 favorable change in warrant fair value lifted other income, resulting in net income attributable to common shareholders of $13,702,407, or $0.01 per basic and diluted share.
For the six months, revenue was $76,532,801 with income from operations of $29,913,453 and net income of $7,817,692 after $7,308,441 of income tax expense. Cash was $26,617,346 as of September 30, 2025, up from $11,315,385, aided by $19,880,115 net cash from operating activities; related party loans of $4,000,000 were repaid. Accounts receivable rose to $40,871,924, and warrant liabilities were $39,789,081. Shares outstanding were 1,074,496,422 as of November 14, 2025. Subsequent to quarter end, the FDA approved Elite’s ANDA for generic Requip XL (Ropinirole ER tablets) under the Elite Laboratories label.
Elite Pharmaceuticals (ELTP) filed an 8-K/A to amend its earlier report, solely to correct the date of its conference call. The company will host the call to discuss financial results for the second quarter of fiscal 2026, covering the period ended September 30, 2025.
The conference call is scheduled for Monday, November 17, 2025, at 11:30 AM EST. Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference number 98840. General questions may be emailed to dianne@elitepharma.com by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025. The information is being furnished under Items 2.02, 7.01 and 9.01 and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced FDA approval for its generic version of Requip XL (Ropinirole Extended-Release Tablets USP). The approval covers 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths used to treat symptoms of Parkinson’s disease. The product will be marketed and sold under the Elite Laboratories, Inc. label.
The company furnished a press release with these details as Exhibit 99.1. Information in this item and the press release is provided under Regulation FD and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced it will host a conference call to discuss its second quarter fiscal 2026 results for the period ended September 30, 2025. The call is scheduled for November 14, 2025, at 11:30 AM EST.
Participants can dial 1-800-346-7359 (domestic) or 1-973-528-0008 (international) and use conference number 98840. Questions may be emailed to dianne@elitepharma.com; general questions are due by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025.
Elite Pharmaceuticals (ELTP) filed a Form 4 disclosing that EVP Operations Douglas Plassche sold common stock. On 10/02/2025, he executed a sale (code S) of 800,000 shares at a price of $0.624 per share. Following the transaction, he beneficially owns 3,500,000 shares, held directly.
The filing identifies the reporting person as an officer (EVP Operations) and indicates the ownership form as direct. No derivative securities transactions were reported in Table II.
FAQ
What is the current stock price of Elite Pharmaceuticals (ELTP)?
What is the market cap of Elite Pharmaceuticals (ELTP)?
